SEC Form 4 · accession 0001209191-17-007681
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Annalisa Jenkins
Officer — President and CEO · Director
Period of report
Feb 1, 2017
Accepted (ET)
Feb 3, 2017 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.90 | Feb 1, 2017 | A | 192,000 | A | — | Jan 31, 2027 | Common Stock | 192,000 | 192,000 | D |
Explanation of responses
- F1This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017.